After a freak accident left him blind and in agony, Phil Durst thought hope was lost. Then, a world-first stem cell trial ...
As the number of LASIK procedures performed in the United States continues to climb, a growing number of prospective patients are asking an important question: “Do I need to stop taking my anxiety ...
Lumata Health Improves Patient Adherence to Vision-Saving Treatments by Alleviating Barriers to Care
New study shows significant improvements in patient treatment adherence with Lumata Health’s Continuous Care model. More than 90% of people with vision impairment have a preventable or treatable cause ...
Even in an era of remarkable therapeutics for neovascular age-related macular degeneration, there remains a lack of therapies to improve vision in dry AMD. Many patients continue to live with central ...
Nick Kharufeh said he never thought he would see out of his left eye again after suffering an injury several years ago. Now, he is advocating for the procedure that restored his vision. The accident ...
STAMFORD, Conn, February 24, 2026--(BUSINESS WIRE)--TECLens, Inc., a clinical-stage ophthalmic medical device company, announced today the treatment of the initial patient for its first-in-human ...
Modern Vision Centers has released a new article titled “The Truth About EVO ICL and Glare: What Research Actually Shows,” addressing one of the most common questions patients have about implantable ...
HYDERABAD, India, Jan. 31, 2026 /PRNewswire/ -- International Health Dialogue (IHD) 2026 opened today in Hyderabad, bringing together clinicians, patient safety leaders, accreditation experts, and ...
Initial case conducted by Dr. David Godfrey at Glaucoma Associates of Texas The IDE study will evaluate the safety and effectiveness of the company's Calibreye™ Titratable Glaucoma Therapy™ (TGT) ...
NEW YORK, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) therapeutics, today ...
Enhancement coverage applies within 24 months of the original procedure for refractive and premium lens pathways. Beyond this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results